Accumulation of the Enterobacterial Common Antigen Lipid II Biosynthetic Intermediate Stimulates *degP* Transcription in *Escherichia coli*

PAUL N. DANESE,[1]† GEORGE R. OLIVER,[1]‡ KATHLEEN BARR,[2] GREGORY D. BOWMAN,[1]
PAUL D. RICK,[2] AND THOMAS J. SILHAVY[1]*

Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544,[1] *and*
Department of Microbiology and Immunology, Uniformed Services University of
the Health Sciences, Bethesda, Maryland 20814-4799[2]

In *Escherichia coli*, transcription of the *degP* locus, which encodes a heat-shock-inducible periplasmic protease, is controlled by two parallel signal transduction systems that each monitor extracytoplasmic protein physiology. For example, the heat-shock-inducible sigma factor, σ^E, controls *degP* transcription in response to the overproduction and folded state of various extracytoplasmic proteins. Similarly, the CpxA/R two-component signal transduction system increases *degP* transcription in response to the overproduction of a variety of extracytoplasmic proteins. Since *degP* transcription is attuned to the physiology of extracytoplasmic proteins, we were interested in identifying negative transcriptional regulators of *degP*. To this end, we screened for null mutations that increased transcription from a strain containing a *degP-lacZ* reporter fusion. Through this approach, we identified null mutations in the *wecE*, $rmlA_{ECA}$, and *wecF* loci that increase *degP* transcription. Interestingly, each of these loci is responsible for synthesis of the enterobacterial common antigen (ECA), a glycolipid situated on the outer leaflet of the outer membrane of members of the family *Enterobacteriaceae*. However, these null mutations do not stimulate *degP* transcription by eliminating ECA biosynthesis. Rather, the *wecE*, $rmlA_{ECA}$, and *wecF* null mutations each impede the same step in ECA biosynthesis, and it is the accumulation of the ECA biosynthetic intermediate, lipid II, that causes the observed perturbations. For example, the lipid II-accumulating mutant strains each (i) confer upon *E. coli* a sensitivity to bile salts, (ii) confer a sensitivity to the synthesis of the outer membrane protein LamB, and (iii) stimulate both the Cpx pathway and σ^E activity. These phenotypes suggest that the accumulation of lipid II perturbs the structure of the bacterial outer membrane. Furthermore, these results underscore the notion that although the Cpx and σ^E systems function in parallel to regulate *degP* transcription, they can be simultaneously activated by the same perturbation.

In *Escherichia coli*, transcription of the *degP* gene, which encodes a heat-shock-inducible periplasmic protease, is modulated by at least two signal transduction systems that function in parallel with respect to each other. The Cpx signal transduction pathway and the σ^E regulatory system each control *degP* transcription in response to extracytoplasmic signals (4, 6, 15, 19, 21, 22). For example, overproduction of outer membrane proteins increases σ^E activity, while mutations that decrease the production of outer membrane proteins concomitantly decrease σ^E activity. The signal transduction system that senses these extracytoplasmic changes has recently been defined, and it consists of an inner membrane anti-sigma factor (RseA) and a periplasmic protein (RseB) that both monitor extracytoplasmic protein physiology (7, 18). A second signal transduction system, comprised of the CpxA-CpxR two-component proteins, also regulates *degP* transcription in response to extracytoplasmic protein physiology (4, 6, 9, 19, 32).

To further characterize the transcriptional regulation of

degP by Cpx and σ^E, we screened for negative regulators of *degP* transcription. Through this approach, we identified null mutations in three genes of the *wec* gene cluster that stimulate *degP* transcription.

The *wec* gene cluster is required for the synthesis of the enterobacterial common antigen (ECA), a glycolipid found in the outer leaflet of the outer membrane in all species of the family *Enterobacteriaceae* (reviewed in references 11, 12, and 24). The polysaccharide portion of ECA consists of three sugar moieties: *N*-acetyl-D-glucosamine (GlcNAc), *N*-acetyl-D-mannosaminuronic acid (ManNAcA), and 4-acetamido-4,6-dideoxy-D-galactose (Fuc4NAc). These sugars form a linear trimeric repeat with the following structure: →3)α-D-Fuc4NAc-(1→4)-β-D-ManNAcA-(1→4)-α-D-GlcNAc-(1→) (Fig. 1) (13). Each polysaccharide chain is ultimately linked to phosphatidic acid via a phosphodiester linkage.

The ECA polysaccharide trimer is synthesized in stepwise fashion at the inner membrane by the successive transfer of the component amino sugars to the lipid carrier, undecaprenyl monophosphate (Fig. 2a). The first step in ECA synthesis is the transfer of GlcNAc-1-phosphate from UDP-GlcNAc to undecaprenyl monophosphate (C_{55}-P) to yield C_{55}-PP-GlcNAc, also known as lipid I. ManNAcA is then transferred from UDP-ManNAcA to lipid I to yield C_{55}-PP-GlcNAc-ManNAcA (lipid II). Finally, Fuc4NAc is transferred from TDP-Fuc4NAc to lipid II to yield a complete lipid-linked trimer, C_{55}-PP-GlcNAc-ManNAcA-Fuc4NAc (lipid III) (1, 16, 25). Subse-

* Corresponding author. Mailing address: Department of Molecular Biology, Princeton University, Princeton, NJ 08544. Phone: (609) 258-5899. Fax: (609) 258-2957. E-mail: tsilhavy@molbio.princeton.edu.
† Present address: Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138.
‡ Present address: University of Texas Southwestern Medical School, Dallas, TX 75235.

FIG. 1. The trisaccharide repeat unit of the ECA polysaccharide moiety. This repeat unit, α-D-Fuc4NAc-(1→4)-β-D-ManNAcA-(1→4)-α-D-GlcNAc, constitutes the amino sugar polymer of ECA. N-Acetylglucosamine (GlcNAc) also serves as the attachment site for the lipid anchor. N-Acetyl-D-mannosaminuronic acid and 4-acetamido-4,6-dideoxy-D-galactose are abbreviated as ManNAcA and Fuc4NAc, respectively. The dashed line representing the bond between the number 6 oxygen and the acetyl group of GlcNAc indicates that the acetyl group is not present in stoichiometric amounts in ECA.

quent steps involve polymerization, transfer of the polymer to a phospholipid aglycone, and translocation to the outer membrane. The nature and chronology of these last three events have not yet been established.

The mutations identified in this study all interfere with the conversion of lipid II to lipid III (Fig. 2). Indeed, the results described here indicate that the accumulation of lipid II stimulates *degP* transcription. Specifically, the lipid II-accumulating mutants can (i) confer upon *E. coli* a sensitivity to bile salts, (ii) confer a sensitivity to the synthesis of the outer membrane protein LamB, and (iii) stimulate both the Cpx pathway and σ^E activity. These phenotypes suggest that the *wec* mutations perturb the structure of the bacterial outer membrane. Moreover, analysis of these mutations underscores the notion that although the Cpx and σ^E systems function in parallel to regulate *degP* transcription, they can be simultaneously activated by the same perturbation (4, 9, 19).

MATERIALS AND METHODS

Media and reagents. Media were prepared as described by Silhavy et al. (28). Liquid cultures were grown in Luria broth. Unless specifically noted, the final concentrations of antibiotics used in growth media were as follows: ampicillin, 50 μg/ml; spectinomycin, 50 μg/ml; and chloramphenicol, 20 μg/ml. Standard microbiological techniques were used for strain construction and bacterial growth (28). 5-Bromo-4-chloro-3-indolyl-D-galactoside (X-Gal) was purchased from Fischer.

Strains and phage. All strain genotypes are provided in the text and figure legends. λRS88, λRS45, and λNK1324 have been described elsewhere (10, 29). The *degP-lacZ* and *rpoH*$_{P3}$-*lacZ* operon fusions have been described elsewhere (6, 15).

Screening for negative regulators of *degP* transcription. Nine independent cultures of MC4100 were infected with λNK1324 (which delivers the Tn*10cam* transposon) as described by Kleckner et al. (10). Infected cells were then plated on Luria agar containing chloramphenicol to select for cells carrying Tn*10cam* insertions. The resulting transductants were grouped into nine independent pools, with each pool containing at least 1,200 colonies.

P1*vir* lysates were prepared on each pool as described by Kleckner et al. (10). The P1 lysates were then used to transduce the Tn*10cam* insertions into PND257 (MC4100; *ompR*::Tn*10* λRS88[*degP-lacZ*]). Transductants were plated on Luria agar containing chloramphenicol and 1.4 μg of X-Gal per ml. The parent strain (PND257) is phenotypically Lac⁻ (white) on this medium, providing a simple screen for mutants with increased *degP* transcription. Eight Lac⁺ (blue) colonies were isolated from each of the nine pools and further analyzed.

The Tn*10cam* insertions within each Lac⁺ mutant were reintroduced into the parent strain (PND257) to determine whether the increase in Lac activity was due to the specific Tn*10cam* insertion. Those mutant strains whose increased Lac activity resulted from the Tn*10cam* insertion were further analyzed. These rebuilt strains were used for subsequent analyses. Each insertion mutation (except insertion 5) was numbered *XY*. The *X* value indicates the pool number (1 to 9) from which the mutation was isolated, while the *Y* value indicates the isolate number (1 to 8) from the given pool. Insertion 5 was isolated in a preliminary

pilot experiment, and as a consequence, it was not given a designated pool number.

Determination of β-galactosidase activity. Cells were grown overnight in Luria broth, then subcultured (1:40) into 2 ml of the same medium, and grown to mid-exponential phase. β-Galactosidase activities were determined by a microtiter plate assay (29). β-Galactosidase activities are expressed as (units/A_{600}) × 10^3, where units = micromoles of product formed per minute. Assays were performed on a minimum of four independent isolates of each strain, and the results were averaged to obtain the indicated activities. Error bars indicate the standard deviations. The absence of error bars indicates that the standard deviation fell below the resolution limit of the graphing program.

Passive hemagglutination assay for the presence of ECA. Determination of the presence of ECA was performed as described elsewhere (24).

Determination of chromosomal insertion sites of the Tn*10cam* insertions. The precise sites of Tn*10cam* insertions were determined in the following manner. Strains carrying the *wecF*::*cam*, *rmlA*$_{ECA}$::*cam*, and *wecE*::*cam* mutations were subjected to arbitrarily primed PCR (2) using the CAM-5′ primer (5′ CTG ACG GGG TGG TGC GTA ACG GC 3′) and the ARB1 primer (5′ GG CCA CGC GTC GAC TAG TAC NNN NNN NNN NGA TAT 3′). The PCR products generated by these two primers were subjected to a secondary amplification step with the CAM-5′ primer and the ARB2 primer (5′ GGC CAC GCG TCG ACT AGT AC 3′). PCR products generated from the second amplification step were sequenced, and the junction between the Tn*10cam* sequence and the host chromosomal DNA was determined from this sequence information.

Specifically, the Tn*10cam* of mutant 5 (*wecF*::*cam*) is inserted between nucleotides 7863 and 7864 of the published *wec* gene cluster sequence (accession no. AE000455). The Tn*10cam* of mutant 31 (*wecE*::*cam*) is inserted between nucleotides 5707 and 5708 of the published *wec* gene cluster sequence, while the Tn*10cam* of insertion 22 (*rmlA*$_{ECA}$::*cam*) is situated between nucleotides 3894 and 3895 of the same sequence.

Assay for lipid II accumulation. The incorporation of [³H]GlcNAc into lipid II was determined as previously described (26). Briefly, bacteria were grown with vigorous aeration at 37°C in 60 ml of Proteose Peptone-beef extract medium supplemented with glucose (0.2% final concentration) to an A_{600} of 0.4. The cells were then harvested by centrifugation, resuspended in fresh Proteose Peptone–beef extract–0.2% glucose (6 ml), and incubated at 37°C with [³H]GlcNAc (75 μCi, 5.2 Ci/mmol) for 30 min. The labeled cells were subsequently poured over crushed ice, harvested by centrifugation, and washed with cold 0.9% saline. The washed cells were then successively extracted with 95% ethanol (6 ml) and acetone (6 ml) and then dried in vacuo. The dried cells were extracted with chloroform-methanol (3:2 [vol/vol]), and the extracts were analyzed by ascending paper chromatography on EDTA-treated silica-gel-impregnated paper with chloroform-methanol-water-concentrated ammonium hydroxide (88:48:10:1 [vol/vol/vol/vol]) as the developing solvent. The material in the region of the chromatogram corresponding to lipid II was eluted, and the amount of radioactivity in this material was determined. In addition, the identity of this material as lipid II disaccharide was verified by treatment of the material with mild acid followed by gel filtration chromatography of the water-soluble fraction on a Bio-Gel P2 column.

Maltose sensitivity disc assays. The maltose sensitivity disc assays, whose results are shown in Fig. 6, were performed as follows. Each strain was grown to saturation overnight at 37°C in 5 ml of Luria broth. Three milliliters of molten Luria top agar (55°C) was mixed with 100 μl of an overnight culture and immediately spread onto Luria agar (warmed to 23°C). The top agar was allowed to solidify for 2 min. A Schleicher and Schuell analytical paper filter disc (7-mm diameter) was then placed in the middle of the Luria agar plate. Ten microliters of 20% (wt/vol) maltose was placed on the filter disc, and the plates were incubated overnight at 37°C. The zone of clearing, which is defined as the diameter of inhibited growth minus the diameter of the filter disc, was measured 18 h after the inception of incubation. Each value shown in Fig. 6 is the average of four replicate experiments. The error bars represent the standard deviations from each average.

Genetic nomenclature. Genes and gene products involved in ECA and O-antigen synthesis and assembly are designated in accordance with the recently formulated bacterial polysaccharide gene nomenclature scheme (23). The following are the relevant new designations, each of which is accompanied by the former designation in parentheses: *wbb* (*rfb*), *wec* (*rfe/rff*), *wecA* (*rfe*), *wzzECA*? (*o349*), *wecB* (*rffE*), *wecC* (*rffD*), *rmlB* (*o355*), *rmlA* (*o292*), *wecD* (*rffC*), *wecE* (*rffA*), *wzx*$_{ECA}$? (*o416*), *wecF* (*rffT*), and *wecG* (*rffM*). In addition, the subscripts ECA and Oag have been included where appropriate to distinguish between homologs involved in ECA and O-antigen synthesis, respectively.

RESULTS

Rationale and mutant isolation. We sought to identify negative regulators of *degP* transcription by generating null mutations that increased transcription from a *degP-lacZ* reporter fusion. To facilitate this analysis, we created strain PND257 (MC4100; *ompR*::Tn*10* λRS88[*degP-lacZ*]), which contains the *degP-lacZ* fusion as well as the *ompR*::Tn*10* null mutation.

a)

b)

FIG. 2. The ECA polysaccharide biosynthetic pathway and the *wec* gene cluster. (a) The ECA polysaccharide biosynthetic pathway. Gene names are listed in italics adjacent to the reactions that their products catalyze. The genes affected by the mutational analysis employed in this study are enclosed within rectangles. Abbreviations: C_{55}-P, undecaprenyl monophosphate; GlcNAc, *N*-acetylglucosamine; ManNAcA, *N*-acetyl-D-mannosaminuronic acid; Fuc4NAc, 4-acetamido-4,6-dideoxy-D-galactose; Glc-1-P, glucose-1-phosphate; PP_i, pyrophosphate; TDP-Glc, TDP-glucose; TDP-4-keto-6-deoxy-D-Glc, TDP-4-keto-6-deoxy-D-glucose; α-KG, α-ketoglutarate; TDP-FucN, TDP-fucosamine; acetyl-CoA, acetyl coenzyme A; Co-ASH, coenzyme A; ManNAc, *N*-acetyl mannose. (b) The *wec* gene cluster. The open reading frames of this cluster are shown in shaded boxes. All open reading frames are transcribed from 5′ to 3′ as shown. The positions of the insertions described in this study are also depicted. A 13,000-bp scale is depicted below the gene cluster for reference.

degP-lacZ, ompR::Tn10

FIG. 3. The Tn*10cam* insertions stimulate *degP-lacZ* transcription. The β-ga-lactosidase activities of PND257 (MC4100; *ompR*::Tn*10* λRS88[*degP-lacZ*]) (lane 1), PND788 (PND257; Tn*10cam* insertion 5) (lane 2), PND789 (PND257; Tn*10cam* insertion 22) (lane 3), and PND790 (PND257; Tn*10cam* insertion 31) (lane 4) were determined. Tn*10cam* insertions 5 and 31 each stimulate *degP-lacZ* transcription approximately sixfold, while insertion 22 stimulates *degP-lacZ* tran-scription approximately threefold compared to the parent strain. All strains were grown as described in Materials and Methods.

ompR null strains do not synthesize the major outer membrane proteins OmpC and OmpF (30), and consequently, σ^E activity is reduced in such strains (15). Because of the reduction in σ^E activity, PND257 is phenotypically Lac⁻ (white) on Luria agar containing 1.4 μg of X-Gal per ml. This Lac⁻ phenotype pro-vides a simple screen for mutants with increased *degP* tran-scription. By generating null mutations throughout the chro-mosome of PND257, we hoped to identify mutants with increased Lac activity, and by extension, mutations that im-paired the function of negative regulators of *degP* transcrip-tion.

We used λNK1324, which delivers the Tn*10cam* transposon (10), to perform transposon mutagenesis on strain PND257. The chloramphenicol-resistant colonies generated by this pro-cedure were screened for those with increased *degP* transcrip-tion. Approximately 15,000 chloramphenicol-resistant colonies were screened, and 11 colonies with increased *degP* transcrip-tion were analyzed. Of these 11 isolates, 9 grew poorly on lactose-MacConkey agar, while the remaining two grew as well as the parent (PND257) on this medium. Since sensitivity to MacConkey agar is often an indicator of a structural pertur-bation in the outer membrane (20), and since *degP* transcrip-tion is attuned to such perturbations (15, 22, 27), we chose to analyze the nine MacConkey agar-sensitive mutants.

Figure 3 shows that each transposon-generated insertion increases *degP* transcription approximately three- to sixfold

compared to the parent strain. For example, insertions 5 and 31 increase *degP* transcription approximately sixfold (Fig. 3, compare lanes 2 and 4 with lane 1), while insertion 22 increases *degP* transcription approximately threefold (Fig. 3, compare lanes 1 and 3). The six remaining transposon-generated muta-tions increase *degP* transcription to the same extent as that observed with insertions 5 and 31 (data not shown).

Null mutations within the *wec* gene cluster stimulate *degP* transcription. The transposon insertions in each of the Mac-Conkey agar-sensitive isolates were all tightly linked to the *wec* gene cluster, which is located at approximately 85 min on the *E. coli* chromosome. Since the *wec* gene cluster is involved in the biosynthesis of ECA, we were interested in determining whether the Tn*10cam* insertions affected the biosynthesis of ECA. Using a passive hemagglutination assay for ECA biosyn-thesis (25), we determined that eight of the nine insertions did not produce ECA (ECA⁻). Only one insertion (no. 22) re-mained ECA⁺. Interestingly, insertion 22 causes the weakest induction of *degP* transcription (Fig. 3).

Fine-structure mapping of each insertion using previously described Tn*10* insertions within the *wec* gene cluster (16) indicated that five of the nine Tn*10cam* insertions (no. 5, 41, 45, 47, and 51) were tightly linked to the *wecE* locus. In addi-tion, three of the nine Tn*10cam* insertions (no. 31, 32, and 33) were tightly linked to the *wecE* locus, while the remaining insertion (no. 22) was tightly linked to the *wecD* locus (Fig. 2b).

Using this linkage information, we then determined the pre-cise sites of insertion of three representative Tn*10cam* inser-tions (no. 5, 22, and 31). The Tn*10cam* of mutant 5 is inserted within the 140th codon of the *wecF* open reading frame. The Tn*10cam* of mutant 31 is situated within the 215th codon of the *wecE* coding sequence, while the Tn*10cam* of mutant 22 is inserted within the 123rd codon of $rmlA_{ECA}$ (see Materials and Methods for the precise nucleotide insertion sites). Thus, our screen identified three distinct loci in the *wec* gene cluster, *wecF*, *wecE*, and $rmlA_{ECA}$. Accordingly, Tn*10cam* insertions 5, 22, and 31 are referred to as *wecF*::*cam*, $rmlA_{ECA}$::*cam*, and *wecE*::*cam*, respectively.

The $rmlA_{ECA}$::*cam* mutation. The $rmlA_{ECA}$::*cam* mutation was anomalous in two major regards. First, unlike the other eight mutations, the $rmlA_{ECA}$::*cam* mutation did not confer an ECA⁻ phenotype, although it mapped within the *wec* gene cluster. Second, the $rmlA_{ECA}$::*cam* mutation conferred a rela-tively weak increase in *degP* transcription (approximately 50% of that observed with the other Tn*10cam* insertions).

A potential explanation of the phenotypes conferred by the $rmlA_{ECA}$::*cam* mutation was provided by previously described biochemical analysis of the $rmlA_{ECA}$ gene product (14). Spe-cifically, the predicted $rmlA_{ECA}$ gene product has 65% identity with $RmlA_{Oag}$, a glucose-1-phosphate thymidylyltransferase that plays a role in the initial stages of TDP-Fuc4NAc biosyn-thesis (33). Marolda and Valvano (14) have demonstrated that the $rmlA_{ECA}$ gene product does indeed display glucose-1-phos-phate thymidylyltransferase activity, thus confirming what the sequence homology between $RmlA_{ECA}$ and $RmlA_{Oag}$ had sug-gested. Given the activity of the $rmlA_{ECA}$ gene product, we predicted that a lesion in this locus would reduce production of TDP-glucose and, hence, slow Fuc4NAc synthesis (Fig. 2a). As a consequence, the $rmlA_{ECA}$::*cam* mutation would slow the production of ECA by impeding the conversion of lipid II to lipid III. However, since a functional $rmlA_{Oag}$ gene product is still present in the *E. coli* chromosome (33), Fuc4NAc synthe-sis and ECA synthesis would be reduced but not abolished. According to this model, a lesion in $rmlA_{ECA}$ would (i) not confer an ECA⁻ phenotype and (ii) display an attenuated increase in *degP* transcription compared with the *wecF* and

TABLE 1. Accumulation of lipid II in Tn*10cam* insertion mutants defective in the synthesis of lipid III

Strain	Relevant genotype	Accumulation of lipid II[a]
PND257	Parent	−
PND788	*wecF*::Tn*10cam*	+
PND789	*rmlA*$_{ECA}$::Tn*10cam*	+
PND790	*wecE*::Tn*10cam*	+

[a] +, >1,000 cpm of [³H]GlcNAc-labeled lipid II was recovered from extracts prepared from approximately 10^8 cells. −, [³H]GlcNAc-labeled lipid II was not detectable in extracts prepared from approximately 10^8 cells.

wecE mutations, which completely abolish the synthesis of lipid III. These predictions are borne out in the data described above (Fig. 3).

One additional prediction is that all of the Tn*10cam* insertions should impede the conversion of lipid II to lipid III (Fig. 2). Indeed, analysis of the PND788 (PND257; *wecF*::*cam*), PND789 (*rmlA*$_{ECA}$::*cam*), and PND790 (*wecE*::*cam*) strains shows that they accumulate significant amounts of lipid II, while their parent strain, PND257, does not accumulate lipid II in detectable quantities (Table 1). This information indicates that (i) the mutations in *wecF* and *wecE* are loss-of-function mutations and (ii) this study provides the first evidence indicating that the *rmlA*$_{ECA}$ gene product is actually involved in ECA biosynthesis.

The accumulation of the lipid II ECA biosynthetic intermediate increases *degP* transcription and confers sensitivity to

bile salts. From the data presented, it is clear that all of the mutations identified in our screen affect the same general step in the biosynthesis of ECA. Specifically, the insertions within *wecF* and *wecE* cause the accumulation of lipid II while the *rmlA*$_{ECA}$::*cam* mutation impedes the conversion of lipid II to lipid III (Fig. 2a).

What is not clear, however, is whether it is the absence of ECA or the accumulation of the lipid II intermediate that stimulates *degP* transcription and confers sensitivity to MacConkey agar. Various tests of epistasis were performed to distinguish between these two possibilities. For example, the *wecA*::Tn*10* mutation was introduced into the *wecF*::*cam*, *wecE*::*cam*, and *rmlA*$_{ECA}$::*cam* strains, and the resulting amounts of *degP* transcription were determined (Fig. 4). The *wecA*::Tn*10* mutation blocks ECA synthesis at its earliest step, preventing the transfer of GlcNAc phosphate from UDP-GlcNAc to undecaprenyl monophosphate (Fig. 2a). If the lack of ECA is the cause of the observed phenotypes, the *wecA*::Tn*10 wecE*::*cam* double mutant strain should display at least the same degree of *degP* transcriptional induction and MacConkey agar sensitivity as observed with the *wecE*::*cam* mutation alone. If the accumulation of lipid II is responsible for the transcriptional induction of *degP*, then the double mutant strain should not display the transcriptional induction observed with the single chloramphenicol-resistant insertion mutations. These predictions also hold true for the *wecF*::*cam* and *rmlA*$_{ECA}$::*cam* mutant strains.

Figure 4 indicates that the accumulation of lipid II is responsible for the observed phenotypes. For example, when the


FIG. 4. The accumulation of lipid II stimulates transcription of *degP-lacZ*. β-Galactosidase activities were determined for the following strains: PND423 (MC4100; *ompR101* λRS88[*degP-lacZ*]) (lane 1), SP173 (PND423; *wecE*::*cam*) (lane 2), SP190 (PND423; *wecE*::*cam wecA*::Tn*10*) (lane 3), SP172 (PND423; *rmlA*$_{ECA}$::*cam*) (lane 4), SP185 (PND423; *rmlA*$_{ECA}$::*cam wecA*::Tn*10*) (lane 5), SP188 (PND423; *rmlA*$_{ECA}$::*cam wecE*::Tn*10*) (lane 6), SP171 (PND423; *wecF*::*cam*) (lane 7), and SP179 (PND423; *wecF*::*cam wecA*::Tn*10*) (lane 8). The *wecA*::Tn*10* mutation blocks the transcriptional induction of *degP-lacZ* that is conferred by the *wecE*::*cam*, *rmlA*$_{ECA}$::*cam*, and *wecF*::*cam* insertions (compare lanes 2 and 3, 4 and 5, and 7 and 8). The weak transcriptional induction of *degP-lacZ* conferred by the *rmlA*$_{ECA}$::*cam* mutation can be increased by the *wecE*::Tn*10* mutation (compare lanes 4 and 6). The *ompR101* mutation is a deletion within the *ompR* open reading frame, rendering the strains described in this figure null for *ompR*. All strains were grown as described in Materials and Methods.

wecA::Tn*10* mutation is introduced into strains containing either the *wecE*::*cam*, *rmlA*$_{ECA}$::*cam*, or *wecF*::*cam* mutation, the double mutant strain shows only a minimal induction of *degP* transcription (Fig. 4, compare lanes 2 and 3, 4 and 5, and 7 and 8). In addition, these double mutant strains are no longer MacConkey agar sensitive.

Finally, based on the biochemical analysis of RmlA$_{ECA}$ (14) and on the homology between the *rmlA*$_{ECA}$ gene product and the RmlA$_{Oag}$ protein, we have suggested that the *rmlA*$_{Oag}$:: *cam* mutation attenuates, but does not abolish, the conversion of lipid II to lipid III. This notion explains the weak induction of *degP* transcription conferred by this mutation, and it also explains why the *rmlA*$_{ECA}$::*cam* lesion does not confer an ECA$^-$ phenotype. If this model is correct, introduction of the *wecE*::Tn*10* mutation into a strain that contains the *rmlA*$_{ECA}$:: *cam* insertion should raise *degP* transcription to the level observed with the *wecE* mutation alone. Again, this prediction is verified. Specifically, the *rmlA*$_{ECA}$ *wecE* double mutant strain displays the same degree of transcriptional induction of *degP* as the *wecE* mutation does in isolation (compare lanes 2, 4, and 6 in Fig. 4).

There are two general conclusions that can be drawn from Fig. 4. First, the accumulation of lipid II stimulates *degP* transcription and confers MacConkey agar sensitivity in these strains. Second, the *rmlA*$_{ECA}$::*cam* mutation impedes, but does not abolish, the conversion of lipid II to lipid III in the biosynthesis of ECA.

The induction of *degP* transcription by accumulation of the lipid II intermediate is decreased in an *ompR*$^+$ background. Since the experiments described above have all utilized strains that were *ompR* null, we were also interested in determining the effects of lipid II accumulation in an *ompR*$^+$ background. Figure 5 shows that while the *wec* mutations still stimulate *degP* transcription in the *ompR*$^+$ background, the magnitude of the induction of *degP* transcription conferred by these mutations is significantly reduced compared to the analogous *ompR* strains. These *ompR*$^+$, lipid II-accumulating strains are also no longer as sensitive to growth on MacConkey agar as their *ompR* counterparts.

Since the major proteins whose synthesis is controlled by OmpR are the outer membrane proteins OmpF and OmpC, it seemed likely that the enhanced *degP* transcriptional induction observed in the *ompR* background was due to the lack of these proteins. Consistent with this observation, production of OmpC in an *ompR*, lipid II-accumulating background reduced the magnitude of transcriptional induction of the *degP* locus (data not shown). Thus, at a minimum, it is the lack of OmpC that heightens the MacConkey agar sensitivity and the increase in *degP* transcription that is observed in the lipid II-accumulating strains.

Accumulation of the lipid II intermediate can confer a sensitivity to high-level synthesis of the outer membrane protein LamB. During the course of this study, we noted that the lipid II-accumulating mutant strains were exquisitely sensitive to growth on maltose and maltodextrins. As a consequence, we wanted to determine if these strains had difficulty growing in the presence of all types of sugars or whether their sensitivity was restricted to growth in the presence of maltose and its oligomers. To this end, we assayed the growth of the lipid II-accumulating strains on Luria agar in the presence of high concentrations of maltose, lactose, and glucose. The lipid II-accumulating strains were sensitive only to maltose, indicating that this sensitivity is not simply a sugar-mediated effect (data not shown).

Since the various phenotypes described for these strains appear to be associated with perturbations in the outer mem-


FIG. 5. Accumulation of lipid II stimulates transcription of *degP-lacZ* in the *ompR*$^+$ background. β-Galactosidase activities were determined for the following strains: PND2000 (MC4100; λRS88[*degP-lacZ*]) (lane 1), SP332 (PND2000; *wecF*::*cam*) (lane 2), SP333 (PND2000; *rmlA*$_{ECA}$::*cam*) (lane 3), and SP334 (PND2000; *wecE*::*cam*) (lane 4). The *wecF*::*cam* and *wecE*::*cam* mutations stimulate *degP-lacZ* transcription approximately 1.6-fold. The *rmlA*$_{ECA}$::*cam* mutation stimulates *degP-lacZ* transcription approximately 1.4-fold compared to the parent strains. All strains were grown as described in Materials and Methods.

brane, the observed maltose sensitivity might be due to high-level synthesis and export of the outer membrane porin LamB (LamB synthesis is induced in the presence of maltose). To address this issue, the *lamB*Δ*60* mutation, which deletes a portion of the LamB signal sequence (and prevents its export across the inner membrane [8]), was introduced into the lipid II-accumulating strains. We then determined if these *lamB*Δ*60* strains were also sensitive to high levels of maltose. Figure 6 indicates that the *lamB*Δ*60* mutation abolishes the sensitivity of the lipid II-accumulating strains to high concentrations of maltose (compare lanes 2 and 6, 3 and 7, and 4 and 8). Thus, the maltose sensitivity observed with these strains is due to high-level export of wild-type LamB, further suggesting that the accumulation of lipid II perturbs the physiology of the outer membrane.

Accumulation of lipid II does not interfere with incorporation or assembly of LamB in the outer membrane. Because of the observed toxicity associated with high-level synthesis of LamB in the lipid II-accumulating mutants, we wanted to determine if these strains displayed defects in the incorporation and assembly of LamB into the outer membrane. To address this issue, we performed two experiments. (i) We examined the amount of LamB protein associated with membrane fractions of a parental strain, PND257 (MC4100; *ompR*::Tn*10* λRS88 [*degP-lacZ*]), as well as derivative strains that accumulate lipid II, PND788 (PND257; *wecF*::*cam*), PND789 (PND257;

FIG. 6. High-level export of the LamB maltoporin in lipid II-accumulating strains is toxic. Ten microliters of 20% maltose was added to filter discs that had been placed on lawns of the following strains: SP299 (MC4100; *ompR101 zja*::Tn*10* linked to *lamB*⁺ λRS88[*degP-lacZ*]) (lane 1), SP301 (SP299; *wecF*::*cam*) (lane 2), SP303 (SP299; *rmlA*ₑCₐ::*cam*) (lane 3), SP305 (SP299; *wecE*::*cam*) (lane 4), SP298 (MC4100; *ompR101 zja*::Tn*10* linked to *lamB*Δ*60* λRS88[*degP-lacZ*]) (lane 5), SP300 (SP298; *wecF*::*cam*) (lane 6), SP302 (SP298; *rmlA*ₑCₐ::*cam*) (lane 7), and SP304 (SP298; *wecE*::*cam*) (lane 8). The *ompR101* allele is a deletion within the *ompR* open reading frame, rendering the strains described in this figure null for *ompR*. The *lamB*Δ*60* mutation deletes part of the coding sequence for the LamB signal sequence (8). Thus, strains containing the *lamB*Δ*60* mutation cannot export LamB across the inner membrane. The values displayed along the *y* axis (zone of clearing) represent the amount of growth inhibition caused by the addition of maltose. The zone of clearing value is defined as the diameter of growth inhibition around the maltose-saturated filter disc, minus the diameter of the filter disc itself (7 mm). All strains were grown at 37°C as described in Materials and Methods.

*rmlA*ₑCₐ::*cam*), and PND790 (PND257; *wecE*::*cam*). (ii) We also examined the kinetics of LamB trimerization in PND257, PND788, PND789, and PND790. None of the lipid II-accumulating strains displayed defects in the incorporation of LamB into membrane fractions, nor did these mutants display defects in the trimerization of LamB (data not shown). Thus, the toxicity associated with high-level synthesis of LamB in lipid II-accumulating mutants is not the result of a gross structural defect in LamB assembly.

The *wecF*::*cam*, *wecE*::*cam*, and *rmlA*ₑCₐ::*cam* mutations increase σᴱ activity. Finally, we were interested in the mechanism(s) by which *degP* transcription was being stimulated as a result of lipid II accumulation. Two regulatory pathways are known to modulate *degP* transcription. As mentioned elsewhere, *degP* transcription can be increased by increasing σᴱ activity, through the RseA/B signal transduction system (15). In addition, *degP* transcription is also regulated by the Cpx two-component signal transduction pathway (6, 22), which functions in parallel with the σᴱ signal transduction pathway (4, 6). To determine the specific route by which the *wecF*::*cam*, *rmlA*ₑCₐ::*cam*, and *wecE*::*cam* mutations functioned to increase *degP* transcription, we introduced each insertion into SP245 (MC4100; *ompR*::Tn*10 rpoH*ₚ₃-*lacZ*). The *rpoH*ₚ₃ pro-


FIG. 7. The *wecF*::*cam*, *rmlA*ₑCₐ::*cam*, and *wecE*::*cam* mutations stimulate σᴱ activity. The β-galactosidase activities of SP245 (MC4100; *ompR*::Tn*10* λRS45[*rpoH*ₚ₃-*lacZ*]) (lane 1), SP282 (SP245; *wecF*::*cam*) (lane 2), SP283 (SP245; *rmlA*ₑCₐ::*cam*) (lane 3), and SP284 (SP245; *wecE*::*cam*) (lane 4) were determined. The *wecF*::*cam* and *wecE*::*cam* mutations stimulate *rpoH*ₚ₃-*lacZ* transcription approximately 2.6-fold. The *rmlA*ₑCₐ::*cam* mutation stimulates *rpoH*ₚ₃-*lacZ* transcription approximately 2.3-fold. All strains were grown as described in Materials and Methods.

moter is recognized solely by RNA polymerases containing the σᴱ subunit. Hence, this fusion provides an assay for only σᴱ activity (6, 15). Figure 7 shows that *rpoH*ₚ₃-*lacZ* transcription is induced by the Tn*10cam* insertions in a qualitatively similar fashion as that observed with the induction of *degP* transcription. For example, the *wecF*::*cam* and *wecE*::*cam* insertions stimulate *rpoH*ₚ₃-*lacZ* transcription approximately 2.6-fold (Fig. 7, compare lane 1 with lanes 2 and 4). The *rmlA*ₑCₐ::*cam* insertion stimulates *rpoH*ₚ₃-mediated transcription approximately 2.3-fold (compare lanes 1 and 3 of Fig. 7).

The *wecF*, *wecE*, and *rmlA*ₑCₐ mutations activate the Cpx signal transduction pathway. The results presented in Fig. 7 demonstrate that the *wecF*, *rmlA*ₑCₐ, and *wecE* mutations activate *degP* transcription, at least in part by stimulating σᴱ activity. However, we were also interested in determining if these mutations stimulated *degP* transcription via the Cpx pathway as well. Accordingly, the *cpxR* null mutation was introduced into the parent strain (PND257) as well as the *wecF*, *rmlA*ₑCₐ, and *wecE* mutant strains (PND788, PND789, and PND790, respectively), and the amount of *degP-lacZ* transcription generated from these strains was quantified. Interestingly, elimination of the Cpx pathway by a *cpxR* null mutation decreases, but does not abolish, the transcriptional induction of *degP* conferred by the *wecF*, *rmlA*ₑCₐ, and *wecE* mutations (Fig. 8). For example, in a *cpxR* background, the *wecF*::*cam* and *wecE*::*cam* mutations stimulate *degP* transcription only 1.6- to 1.7-fold (Fig. 8, compare lane 5 with lanes 6 and 8). Similarly, the *rmlA*ₑCₐ::*cam* mutation stimulates *degP* transcription approximately 1.4-fold in the *cpxR* background (Fig. 8, compare lanes 5 and 7). Although the transcriptional induction of *degP* is qualitatively similar in the *cpxR*⁺ and *cpxR*

FIG. 8. The *wecF*::*cam*, *rmlA*$_{ECA}$::*cam*, and *wecE*::*cam* mutations activate the Cpx signal transduction pathway. The β-galactosidase activities of PND257 (MC4100 *ompR*::Tn*10* λRS88[*degP-lacZ*]) (lane 1), PND788 (PND257 *wecF*::*cam*) (lane 2), PND789 (PND257 *rmlA*$_{ECA}$::*cam*) (lane 3), PND790 (PND257 *wecE*::*cam*) (lane 4), SP150 (PND257 *cpxR*::*spec*) (lane 5), SP231 (SP150 *wecF*::*cam*) (lane 6), SP232 (SP150 *rmlA*$_{ECA}$::*cam*) (lane 7), and SP233 (SP150 *wecE*::*cam*) (lane 8) were determined. The *wecF*::*cam* and *wecE*::*cam* mutations stimulate *degP-lacZ* transcription 1.6- to 1.7-fold in the absence of CpxR. Similarly, the *rmlA*$_{ECA}$::*cam* mutation stimulates *degP-lacZ* transcription approximately 1.4-fold in the absence of CpxR. This is in contrast to the three- to sixfold stimulation conferred by these mutations in the presence of CpxR (lanes 1 to 4). All strains were grown as described in Materials and Methods.

background, CpxR is clearly responsible for the majority of the *degP* transcriptional induction in the parental background (PND257). For instance, the *wecF*::*cam* mutation stimulates *degP* transcription approximately 6-fold in the *cpxR*$^+$ background, but only 1.7-fold in the *cpxR* background (Fig. 8, compare lanes 1 and 2 with lanes 5 and 6).

Since the transcriptional induction of *degP* is partially blocked by the *cpxR* null mutation, and since the *wecF*, *rmlA*$_{ECA}$, and *wecE* mutations also increase transcription of *rpoH*$_{P3}$-*lacZ*, these mutations must activate both signal transduction pathways that are known to control *degP* transcription.

DISCUSSION

In our search for negative regulators of *degP* transcription, we have shown that mutations that cause the accumulation of the lipid II intermediate in the pathway for ECA biosynthesis cause several envelope-associated perturbations. First, these mutations confer a sensitivity to growth in the presence of bile salt detergents, which is a classic indicator of an outer membrane permeability defect (20). Second, these mutations confer a sensitivity to high-level export of the wild-type LamB porin,

also suggesting a perturbation in outer membrane physiology. Third, these mutations increase *degP* transcription by stimulating both the σ^E modulatory signal transduction system (15) and the Cpx signal transduction system (6, 22). Since *degP* encodes a periplasmic protease that destroys misfolded extracytoplasmic proteins (see reference 17), this is also an indicator of a perturbation in the physiology of periplasmic and/or outer membrane proteins. Taken together, these results imply that lipid II accumulation perturbs the physiology of envelope proteins, thus causing an increase in *degP* transcription.

Accumulation of lipid II. The results presented in Fig. 4 demonstrate that it is the accumulation of lipid II that stimulates *degP* transcription. Moreover, previous studies have also noted a toxicity associated with the accumulation of lipid II. For example, Rick et al. (26) have observed that *Salmonella typhimurium* strains containing a lesion in *rmlA*$_{Oag}$ (which encodes a homolog of RmlA$_{ECA}$) accumulate the lipid II intermediate and display sensitivity to sodium dodecyl sulfate (SDS). This SDS-sensitive phenotype can be suppressed by mutations that block the accumulation of lipid II.

Despite the body of evidence indicating that lipid II accumulation confers a host of envelope-associated defects, it is unclear why lipid II accumulation exerts these effects. While ECA is not essential for the viability of *E. coli*, the undecaprenyl carrier lipid that is used to synthesize the ECA trisaccharide is essential. We considered the possibility that lipid II accumulation indirectly impeded the synthesis of the peptidoglycan layer and/or lipopolysaccharide by sequestering undecaprenyl monophosphate (C$_{55}$-P). However, overproduction of the BacA protein, which is believed to increase the pool of free C$_{55}$-P (3), had no ameliorative effect on the lipid II-associated phenotypes (6a). Thus, it seems unlikely that the accumulation of lipid II exerts its effects by sequestering C$_{55}$-P.

An alternative model posits that the partially completed ECA trisaccharide may interfere with the biogenesis of envelope proteins, thus altering the permeability of the outer membrane and signaling for increased levels of the envelope protease, DegP. This interference would most likely occur at or near the inner membrane since the lipid II disaccharide remains attached to its undecaprenyl carrier lipid in the inner membrane. According to this view, the accumulation of lipid II in the inner membrane affects some process(es) that is important for outer membrane biogenesis.

The involvement of *rmlA*$_{ECA}$ in ECA biosynthesis. The results presented here also represent the first mutational analysis of *rmlA*$_{ECA}$. Previous studies that have sought mutations in genes involved in ECA biosynthesis have uncovered several loci in the *wec* and *wbb* gene clusters. For example, mutations in *wecB*, *wecC*, *wecD*, *wecE*, *wecF*, and *wecG* have all been identified because of their abolition of ECA biosynthesis (Fig. 2) (16).

Indeed, *rmlA*$_{Oag}$ mutations (Fig. 2a) have also been shown to radically reduce (but not abolish) ECA biosynthesis in *S. typhimurium* (26). However, despite the homology between RmlA$_{ECA}$ and RmlA$_{Oag}$, no mutations were ever identified in *rmlA*$_{ECA}$. Based on the previous analyses and on the results presented here, we suggest that RmlA$_{ECA}$ and RmlA$_{Oag}$ perform redundant functions for the biosynthesis of ECA. The reasons for suggesting this are threefold. First, RmlA$_{ECA}$ and RmlA$_{Oag}$ have 65% amino acid sequence identity, and they each display glucose-1-phosphate thymidylyltransferase activity (14). Second, *rmlA*$_{Oag}$ null strains do not completely abolish ECA biosynthesis in *S. typhimurium*. Finally, Fig. 4 clearly demonstrates that the accumulation of lipid II stimulates *degP* transcription. If RmlA$_{ECA}$ partially contributes to the conversion of lipid II to lipid III, then inactivation of this locus should

display an attenuated increase in *degP* transcription and should remain ECA$^+$. Moreover, when the *rmlA*$_{ECA}$ null mutation is combined with a second mutation that completely abolishes the conversion of lipid II to lipid III (i.e., *wecE*), the second mutation should raise the transcriptional induction of *degP* from the attenuated response observed with only the *rmlA*$_{ECA}$ mutation to the strong induction observed with the *wecE* mutation. All of these predictions are verified by the results presented here.

Thus, although the *rmlA*$_{ECA}$ locus appears to be involved in the biosynthesis of ECA, its identification in this role has been lacking because mutational inactivation of this locus is phenotypically masked by its functional homolog, *rmlA*$_{Oag}$.

The lack of porin enhances the susceptibility of *E. coli* to lipid II accumulation. From the results of Fig. 3 and 5, it is clear that strains lacking the outer membrane porins OmpF and OmpC are more susceptible to the toxic effects of lipid II accumulation. The reasons for this enhanced susceptibility are at present unclear. It is possible that the lack of OmpF and OmpC directly alters the structure of the outer membrane, perhaps making this membrane more susceptible to the perturbations caused by the accumulation of lipid II. For example, lipid II accumulation may increase the ability of the outer membrane to be solubilized by bile salts when OmpF and OmpC are absent.

Alternatively, we note that the lack of porins in an *ompR* background decreases the expression of the σ^E regulon (including *degP*) by approximately fourfold (15). Since σ^E regulation is involved in responding to extracytoplasmic protein stresses, *ompR* strains (i.e., σ^E attenuated) may not be equipped to properly cope with large-scale perturbations, such as those caused by the accumulation of lipid II. However, since the precise biochemical effect(s) of lipid II accumulation is not known, we cannot at present distinguish among these possibilities.

The export-associated toxicity of LamB. To our knowledge, this study describes the first instance in which export of the wild-type LamB protein is toxic. The requirement for export of LamB is specific, as expression of the nonexportable LamBΔ60 mutant is not toxic. Interestingly, this toxicity is not due to a gross structural defect in the assembly of LamB. However, we cannot exclude the possibility that a minor structural alteration in LamB assembly (not detectable by membrane fractionation or trimerization studies) confers this toxicity. Alternatively, the transit of large amounts of LamB protein en route to the outer membrane may confer the toxicity observed in the lipid II-accumulating strains. Suppressor analysis may ultimately be informative as to the precise molecular nature of this toxicity.

Transcriptional induction of *degP*. Finally, we note that the lipid II-mediated induction of *degP* transcription is mediated by increases in both Cpx and σ^E activity (Fig. 7 and 8).

While lipid II accumulation manifests several phenotypes, all of these phenotypes intimate a perturbation in the structure of the outer membrane (e.g., SDS sensitivity, bile salt sensitivity, toxicity of export of LamB, and increased transcription of *degP*). The fact that lipid II accumulation stimulates both signal transduction pathways that control *degP* transcription further supports the hypothesis that both of these signal transduction pathways monitor extracytoplasmic stress (5, 6, 9, 15, 32). Moreover, the activation of both pathways indicates that under some circumstances both Cpx and σ^E are affected by the same types of extracytoplasmic stresses.

ACKNOWLEDGMENTS

REFERENCES

1. **Barr, K., and P. D. Rick.** 1987. Biosynthesis of enterobacterial common antigen in *Escherichia coli. In vitro* synthesis of lipid-linked intermediates. J. Biol. Chem. **262:**7142–7150.
2. **Caetano-Annoles, G.** 1993. Amplifying DNA with arbitrary oligonucleotide primers. PCR Methods Appl. **3:**85–92.
3. **Cain, B. D., P. J. Norton, W. Eubanks, H. S. Nick, and C. M. Allen.** 1993. Amplification of the *bacA* gene confers bacitracin resistance to *Escherichia coli.* J. Bacteriol. **175:**3784–3789.
4. **Connolly, L., A. de las Peñas, B. M. Alba, and C. A. Gross.** 1997. The response to extracytoplasmic stress in *Escherichia coli* is controlled by partially overlapping pathways. Genes Dev. **11:**2012–2021.
5. **Cosma, C. L., P. N. Danese, J. H. Carlson, T. J. Silhavy, and W. B. Snyder.** 1995. Activation of the Cpx two-component signal transduction pathway in *Escherichia coli* suppresses envelope-associated stresses. Mol. Microbiol. **18:**491–505.
6. **Danese, P. N., W. B. Snyder, C. L. Cosma, L. J. B. Davis, and T. J. Silhavy.** 1995. The Cpx two-component signal transduction pathway of *Escherichia coli* regulates transcription of the gene specifying the stress-inducible periplasmic protease, DegP. Genes Dev. **9:**387–398.
6a. **Danese, P. N., G. R. Oliver, and T. J. Silhavy.** Unpublished observation.
7. **de las Peñas, A., L. Connolly, and C. A. Gross.** 1997. The σ^E-mediated response to extracytoplasmic stress in *Escherichia coli* is transduced by RseA and RseB, two negative regulators of σ^E. Mol. Microbiol. **24:**373–385.
8. **Emr, S. D., and T. J. Silhavy.** 1980. Mutations affecting localization of an *Escherichia coli* outer membrane protein, the bacteriophage lambda receptor. J. Mol. Biol. **141:**63–90.
9. **Jones, C. H., P. N. Danese, J. S. Pinkner, T. J. Silhavy, and S. J. Hultgren.** 1997. The chaperone-assisted membrane release and folding pathway is sensed by two signal transduction systems. EMBO J. **16:**6394–6406.
10. **Kleckner, N., J. Bender, and S. Gottesman.** 1991. Uses of transposons with emphasis on Tn*10*. Methods Enzymol. **204:**139–180.
11. **Kuhn, H. M., U. Meier-Dieter, and H. Mayer.** 1988. ECA, the enterobacterial common antigen. FEMS Microbiol. Rev. **4:**195–222.
12. **Mäkelä, P. H., and H. Mayer.** 1976. Enterobacterial common antigen. Bacteriol. Rev. **40:**591–632.
13. **Männel, D., and H. Mayer.** 1978. Isolation and chemical characterization of the enterobacterial common antigen. Eur. J. Biochem. **86:**361–370.
14. **Marolda, C. L., and M. A. Valvano.** 1995. Genetic analysis of the dTDP-rhamnose biosynthesis region of the *Escherichia coli* VW187 (O7:K1) *rfb* gene cluster: identification of functional homologs of *rfbB* and *rfbA* in the *rff* cluster and correct location of the *rffE* gene. J. Bacteriol. **177:**5539–5546.
15. **Mecsas, J., P. E. Rouvière, J. W. Erickson, T. J. Donohue, and C. A. Gross.** 1993. The activity of σ^E, an *Escherichia coli* heat-inducible σ-factor, is modulated by expression of outer membrane proteins. Genes Dev. **7:**2618–2628.
16. **Meier-Dieter, U., R. Starman, K. Barr, H. Mayer, and P. D. Rick.** 1990. Biosynthesis of enterobacterial common antigen in *Escherichia coli*. Biochemical characterization of Tn*10* insertion mutants defective in enterobacterial common antigen synthesis. J. Biol. Chem. **265:**13490–13497.
17. **Misra, R., A. Peterson, T. Ferenci, and T. J. Silhavy.** 1991. A genetic approach for analyzing the pathway of LamB assembly into the outer membrane of *Escherichia coli*. J. Biol. Chem. **266:**13592–13597.
18. **Missiakas, D., M. P. Mayer, M. Lemaire, C. Georgopoulos, and S. Raina.** 1997. Modulation of the *Escherichia coli* σ^E (RpoE) heat-shock transcription-factor activity by the RseA, RseB and RseC proteins. Mol. Microbiol. **24:**355–371.
19. **Missiakas, D., and S. Raina.** 1997. Signal transduction pathways in response to protein misfolding in the extracytoplasmic compartments of *E. coli*: role of two new phosphoprotein phosphatases PrpA and PrpB. EMBO J. **16:**1670–1685.
20. **Nikaido, H., and M. Vaara.** 1985. Molecular basis of bacterial outer membrane permeability. Microbiol. Rev. **49:**1–32.
21. **Pogliano, J., A. S. Lynch, D. Belin, E. C. Lin, and J. Beckwith.** 1997. Regulation of *Escherichia coli* cell envelope proteins involved in protein folding and degradation by the Cpx two-component system. Genes Dev. **11:**1169–1182.
22. **Raina, S., D. Missiakas, and C. Georgopoulos.** 1995. The *rpoE* gene encoding the sigma E (sigma 24) heat shock sigma factor of *Escherichia coli*. EMBO J. **14:**1043–1055.
23. **Reeves, P. R., M. Hobbs, M. A. Valvano, M. Skurnik, C. Whitfield, D. Coplin, N. Kido, J. Klena, D. Maskell, C. Raetz, and P. D. Rick.** 1996. Bacterial polysaccharide synthesis and gene nomenclature. Trends Microbiol. **4:**495–503.
24. **Rick, P. D., and R. P. Silver.** 1996. Enterobacterial common antigen and capsular polysaccharides, p. 104–122. *In* F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli* and *Salmonella*: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C.

25. **Rick, P. D., H. Mayer, B. A. Neumeyer, S. Wolski, and D. Bitter-Suermann.** 1985. Biosynthesis of enterobacterial common antigen. J. Bacteriol. **162:**494–503.

26. **Rick, P. D., S. Wolski, K. Barr, S. Ward, and L. Ramsay-Sharer.** 1988. Accumulation of a lipid-linked intermediate in enterobacterial common antigen synthesis in mutants lacking dTDP-glucose pyrophosphorylase. J. Bacteriol. **170:**4008–4014.

27. **Rouvière, P. E., A. de las Peñas, J. Mecsas, C. Z. Lu, K. E. Rudd, and C. A. Gross.** 1995. *rpoE*, the gene encoding the second heat-shock sigma factor, σ^E, in *Escherichia coli*. EMBO J. **14:**1032–1042.

28. **Silhavy, T. J., M. L. Berman, and L. W. Enquist.** 1984. Experiments with gene fusions. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

29. **Simons, R. W., F. Houman, and N. Kleckner.** 1987. Improved single and multicopy *lac*-based cloning vectors for protein and operon fusion. Gene **53:**85–96.

30. **Slauch, J. M., and T. J. Silhavy.** 1991. *cis*-acting *ompF* mutations that result in OmpR-dependent constitutive expression. J. Bacteriol. **173:**4039–4048.

31. **Slauch, J. M., S. Garrett, D. E. Jackson, and T. J. Silhavy.** 1988. EnvZ functions through OmpR to control porin gene expression in *Escherichia coli* K-12. J. Bacteriol. **170:**439–441.

32. **Snyder, W. B., L. J. B. Davis, P. N. Danese, C. L. Cosma, and T. J. Silhavy.** 1995. Overproduction of NlpE, a new outer-membrane lipoprotein, suppresses the toxicity of periplasmic LacZ by activation of the Cpx signal transduction pathway. J. Bacteriol. **177:**4216–4223.

33. **Stevenson, G., B. Neal, D. Liu, M. Hobbs, N. H. Packer, M. Batley, J. W. Redmond, L. Lindquist, and P. Reeves.** 1994. Structure of the O antigen of *Escherichia coli* K-12 and the sequence of its *rfb* gene cluster. J. Bacteriol. **176:**4144–4156.